Bipolar Doesn't Exist*

Bipolar I disorder is a biologically meaningful syndrome with substantial genetic and molecular evidence, but syndromic diagnosis and treatment response do not by themselves uniquely adjudicate upstream etiology. Established secondary manic syndromes demonstrate that a manic phenotype can arise from more than one causal pathway. Thiamine deficiency and genetically defined thiamine-dependent disorders can produce substantial neuropsychiatric dysfunction, although no adequately documented human case identified in the targeted evidence audit establishes thiamine dysfunction as the cause of bona fide mania or hypomania in reasonably clear sensorium. The most direct randomized Bipolar I mania trial of adjunctive vitamin B1 identified in the present audit did not meet its prespecified antimanic significance criterion, and no responder-specific thiamine-dependent physiological enrichment or validated acquired-state marker presently identifies the proposed cerebral Layer-C state. Whole-blood thiamine diphosphate/pyrophosphate is a systemic status measure; published clinically supported Wernicke cases with in-range pretreatment values show that an in-range result does not categorically exclude Wernicke encephalopathy, but those cases do not establish occult cerebral dysfunction in Bipolar I. This paper therefore advances a narrower, falsifiable hypothesis: a reproducible and clinically meaningful subset of patients currently diagnosed with Bipolar I may have thiamine-dependent cerebral dysfunction materially contributing to the psychiatric phenotype. Within that proposed subgroup, the author further predicts that manic/mixed and depressive phenotypes may occupy different regions of a changing physiological state in which effective capacity and prevailing demand jointly determine remaining functional margin. Manic or mixed activation is predicted to occur preferentially within an intermediate region of constrained physiology that still supports substantial output, whereas further deterioration may favor a lower-output depressive/exhaustive phenotype. The author also predicts that an independently defined difficult-treatment stratum may show greater abnormality on a prespecified thiamine-dependent physiological endpoint than excellent responders and appropriate controls, and that the subgroup may prove substantial; prevalence is presently unknown. The hypothesis is embedded within, rather than substituted for, established bipolar biology through prespecified causal models in which thiamine-dependent physiology may be incidental, independently contributory, downstream of established bipolar biology, or upstream of intermediate systems dysfunction. The present evidence does not establish the proposed subgroup or its predicted state-transition dynamics. It does, however, define a biologically plausible, methodologically unresolved, experimentally discriminable question that warrants direct prospective testing.